FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to NSCLC
Related studies linked through entity extraction aliases.
FGFR Inhibitor in FGFR Dysregulated Cancer
- Status
- TERMINATED
- Phase
- PHASE2
A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive
- Status
- COMPLETED
- Phase
- PHASE2
Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)
- Status
- COMPLETED
- Phase
- PHASE2
Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC
- Status
- UNKNOWN
- Phase
- PHASE4
First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy
- Status
- COMPLETED
- Phase
- N/A
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Registry to Evaluate the Performance of the BDX-XL2 Test
- Status
- COMPLETED
- Phase
- N/A
IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib
- Status
- TERMINATED
- Phase
- PHASE2
18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy
- Status
- COMPLETED
- Phase
- N/A
Descriptive Observational Study ALK-2016-CPHG
- Status
- COMPLETED
- Phase
- N/A
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma
- Status
- UNKNOWN
- Phase
- PHASE3
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Monitoring of Circulating Tumor DNA and Its Aberrant Methylation in the Surveillance of Surgical Lung Cancer Patients (MEDAL, MEthylation Based Dynamic Analysis for Lung Cancer).
- Status
- UNKNOWN
- Phase
- N/A
A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations
- Status
- UNKNOWN
- Phase
- NA